Palvella Therapeutics, Inc (PVLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Palvella Therapeutics, Inc (PVLA) has a cash flow conversion efficiency ratio of -0.047x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.86 Million) by net assets ($232.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PVLA net asset quality index to measure how much of total assets are equity-financed.
Palvella Therapeutics, Inc - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Palvella Therapeutics, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Palvella Therapeutics, Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Palvella Therapeutics, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Palvella Therapeutics, Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Longshine Technology Co Ltd
SHE:300682
|
0.021x |
|
Eternal Asia Supply Chain Management Ltd
SHE:002183
|
-0.011x |
|
Shenzhen Dynanonic Co Ltd
SHE:300769
|
-0.044x |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
0.056x |
|
Sunstone Hotel Investors Inc
NYSE:SHO
|
0.028x |
|
Luxin Venture Capital Group Co Ltd
SHG:600783
|
0.009x |
|
China-Singapore Suzhou Industrial Park Development Group Co Ltd
SHG:601512
|
0.010x |
|
Kfin Technologies Limited
NSE:KFINTECH
|
0.108x |
Annual Cash Flow Conversion Efficiency for Palvella Therapeutics, Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Palvella Therapeutics, Inc from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see PVLA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.98 Million | $-25.01 Million | -0.894x | -416.11% |
| 2024-12-31 | $62.61 Million | $-10.84 Million | -0.173x | -104.90% |
| 2023-12-31 | $-3.88 Million | $-13.70 Million | 3.532x | +451.51% |
| 2022-12-31 | $-23.17 Million | $-14.84 Million | 0.640x | +524.31% |
| 2021-12-31 | $50.76 Million | $-7.66 Million | -0.151x | +89.80% |
| 2020-12-31 | $31.03 Million | $-45.90 Million | -1.479x | -- |
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 cl… Read more